VRC07-523-LS
Indication: HIV prevention in infants and adults
Population PK simulator for VRC07-523LS broadly neutralizing HIV antibody in infants and adults. Two-compartment model with zero-order SC absorption from Huynh et al. JAC 2026. Simulates concentration-time profiles and PT80 neutralization ratios.
Drug Overview
Clinical Context
- Molecular Target
- HIV-1 gp41/gp120
- Drug Class
- Broadly Neutralizing Antibody (bNAb)
- Therapeutic Area
- HIV Prevention
- Indication
- HIV prevention in infants and adults
- Route of Administration
- SC, IV
Model Information
- Model Type
- 2-CMT PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for VRC07-523-LS allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT PopPK model characterizes the pharmacokinetics of this broadly neutralizing antibody (bnab) following sc, iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the VRC07-523-LS PK simulator?
This is a free, interactive pharmacokinetic simulator for VRC07-523-LS used in HIV prevention in infants and adults. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does VRC07-523-LS belong to?
VRC07-523-LS is classified as a Broadly Neutralizing Antibody (bNAb) that targets HIV-1 gp41/gp120. It is used in the HIV Prevention therapeutic area.
What route of administration does this model simulate?
This simulator models SC, IV administration of VRC07-523-LS. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Ready to Simulate?
Launch the VRC07-523-LS simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community